August 2008
Worldwide Biotech;Aug2008, Vol. 20 Issue 8, p5
Trade Publication
The article announces that the development of fexinidazole for the treatment of African trypanosomiasis by the Drugs for Neglected Diseases initiative (DNDi) is to be honored as one of the initiative's Success Stories of the Year.


Related Articles

  • State of the Art in African Trypanosome Drug Discovery. Jacobs, Robert T.; Nare, Bakela; Phillips, Margaret A. // Current Topics in Medicinal Chemistry;May2011, Vol. 11 Issue 10, p1255 

    African sleeping sickness is endemic in sub-Saharan Africa where the WHO estimates that 60 million people are at risk for the disease. Human African trypanosomiasis (HAT) is 100% fatal if untreated and the current drug therapies have significant limitations due to toxicity and difficult...

  • Finding New Hits in Neglected Disease Projects: Target or Phenotypic Based Screening? Gilbert, Ian H.; Leroy, Didier; Frearson, Julie A. // Current Topics in Medicinal Chemistry;May2011, Vol. 11 Issue 10, p1284 

    In this article, we discuss the merits of both target-based and phenotypic screening strategies to find starting points for drug discovery projects in neglected tropical disease including: human African trypanosomiasis, Chagas disease, leishmaniasis and malaria. Technological advances now mean...

  • BIO 2008: Waking up to sleeping sickness.  // Australian Life Scientist;6/6/2008, p1 

    WA company Epichem and the Drugs for Neglected Diseases initiative are collaborating to develop new drugs to treat African sleeping sickness and similar, forgotten diseases.

  • LC-MS-based absolute metabolite quantification: application to metabolic flux measurement in trypanosomes. Kim, Dong-Hyun; Achcar, Fiona; Breitling, Rainer; Burgess, Karl; Barrett, Michael // Metabolomics;Dec2015, Vol. 11 Issue 6, p1721 

    Human African trypanosomiasis is a neglected tropical disease caused by the protozoan parasite, Trypanosoma brucei. In the mammalian bloodstream, the trypanosome's metabolism differs significantly from that of its host. For example, the parasite relies exclusively on glycolysis for energy...

  • Lifeline. Hollingham, Richard // New Scientist;1/15/2005, Vol. 185 Issue 2482, p40 

    This article reports that melarsoprol, is the only available treatment for advanced African sleeping sickness, is a toxic mixture injected intravenously every few days for four weeks. Almost all tropical diseases, from malaria to Leishmaniasis, are neglected by modern medicine. Creating new...

  • Trypanosome Prereplication Machinery: A Potential New Target for an Old Problem. Calderano, Simone Guedes; de Melo Godoy, Patricia Diogo; da Cunha, Julia Pinheiro Chagas; Elias, Maria Carolina // Enzyme Research;2011, p1 

    Approximately ten million people suffer from Chagas disease worldwide, caused by Trypanosoma cruzi, with the disease burden predominately focused in Latin America. Sleeping sickness is another serious health problem, caused by Trypanosoma brucei, especially in sub-Saharan countries....

  • Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies. Burri, Christian; Yeramian, Patrick D.; Allen, James L.; Merolle, Ada; Serge, Kazadi Kyanza; Mpanya, Alain; Lutumba, Pascal; Mesu, Victor Kande Betu Ku; Bilenge, Constantin Miaka Mia; Lubaki, Jean-Pierre Fina; Mpoto, Alfred Mpoo; Thompson, Mark; Munungu, Blaise Fungula; Manuel, Francisco; Josenando, Théophilo; Bernhard, Sonja C.; Olson, Carol A.; Blum, Johannes; Tidwell, Richard R.; Pohlig, Gabriele // PLoS Neglected Tropical Diseases;2/16/2016, Vol. 10 Issue 2, p1 

    Background: Sleeping sickness (human African trypanosomiasis [HAT]) is caused by protozoan parasites and characterized by a chronic progressive course, which may last up to several years before death. We conducted two Phase 2 studies to determine the efficacy and safety of oral pafuramidine in...

  • Postgraduate student awarded for advances in fighting African sleeping disease.  // Chemistry in Australia;Aug2014, p35 

    The article announces Monash University pharmacy doctorate candidate Lori Ferrins as the recipient of the BASF Science and Technology Award for her study on innovations in treating African sleeping disease.

  • Enzyme Inhibitor Offers Hope for Trypanosomiasis Treatment. Kingman, Sharon // BioWorld International;4/14/2010, Vol. 15 Issue 15, p1 

    The article reports on the discovery of a compound which can cure human African trypanosomiasis (HAT) in mice. The drug, which can be taken orally, is expected to undergo human trials in approximately 18 months. According to Paul Wyatt, professor of drug discovery and head of the drug discovery...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics